Table 1.
Patient, tumor and facility characteristics by post-RP management strategy
| All (n = 7,791) |
Observation (n = 4,889) |
ADT Alone (n = 1,571) |
RT Alone (n = 355) |
ADT & RT (n = 976) |
|
|---|---|---|---|---|---|
| Age (years) | 62 (57, 67) | 63 (57, 67) | 63 (57, 67) | 61 (55, 66) | 61 (55, 65) |
| CCI | |||||
| 0 | 6,375 (82%) | 3,958 (81%) | 1,291 (82%) | 306 (86%) | 820 (84%) |
| ≥1 | 1,416 (18%) | 931 (19%) | 280 (18%) | 49 (14%) | 156 (16%) |
| Race | |||||
| White | 6,365 (82%) | 3,973 (81%) | 1,296 (83%) | 280 (79%) | 816 (84%) |
| Other | 1,310 (17%) | 838 (17%) | 250 (16%) | 69 (19%) | 153 (16%) |
| Unknown | 116 (1%) | 78 (2%) | 25 (2%) | 6 (2%) | 7 (<1%) |
| Insurance | |||||
| Private | 4,501 (58%) | 2,805 (57%) | 853 (54%) | 220 (62%) | 623 (64%) |
| Medicare | 2,677 (34%) | 1,747 (36%) | 559 (36%) | 94 (26%) | 277 (28%) |
| Medicaid/other | 329 (4%) | 177 (4%) | 89 (6%) | 17 (5%) | 46 (5%) |
| Uninsured | 205 (3%) | 111 (2%) | 52 (3%) | 18 (5%) | 24 (2%) |
| Unknown | 79 (1%) | 49 (1%) | 18 (1%) | 6 (2%) | 6 (<1%) |
| Median income | |||||
| <$38,000 | 1,207 (15%) | 728 (15%) | 256 (16%) | 73 (21%) | 150 (15%) |
| $38,000–$47,999 | 1,713 (22%) | 1,043 (21%) | 392 (25%) | 75 (21%) | 203 (21%) |
| $48,000–$62,999 | 2,081 (27%) | 1,311 (27%) | 399 (25%) | 98 (28%) | 273 (28%) |
| ≥$63,000 | 2,727 (35%) | 1,767 (36%) | 514 (33%) | 105 (30%) | 341 (35%) |
| Unknown | 63 (<1%) | 40 (<1%) | 10 (<1%) | 4 (1%) | 9 (<1%) |
| Urbanicity | |||||
| Metropolitan | 6,260 (80%) | 3,955 (81%) | 1,228 (78%) | 293 (83%) | 784 (80%) |
| Non-metropolitan | 1,320 (17%) | 795 (16%) | 302 (19%) | 55 (15%) | 168 (17%) |
| Missing | 211 (3%) | 139 (3%) | 41 (3%) | 7 (2%) | 24 (2%) |
| Facility location | |||||
| Northeast | 1,426 (18%) | 973 (20%) | 230 (15%) | 50 (14%) | 173 (18%) |
| Midwest | 2,303 (30%) | 1,295 (26%) | 593 (38%) | 91 (26%) | 324 (33%) |
| South | 2,434 (31%) | 1,581 (32%) | 424 (27%) | 156 (44%) | 273 (28%) |
| West | 1,623 (21%) | 1,038 (21%) | 323 (21%) | 57 (16%) | 205 (21%) |
| Unknown | 5 (<1%) | 2 (<1%) | 1 (<1%) | 1 (<1%) | 1 (<1%) |
| Facility designation | |||||
| Academic | 3,930 (50%) | 2,457 (50%) | 903 (57%) | 128 (36%) | 442 (45%) |
| Non-academic | 3,856 (49%) | 2,430 (50%) | 667 (42%) | 226 (64%) | 533 (55%) |
| Unknown | 5 (<1%) | 2 (<1%) | 1 (<1%) | 1 (<1%) | 1 (<1%) |
| Facility case volume (cases per year) | 4 (2, 9) | 4 (2, 10) | 4 (2, 10) | 2 (1, 4) | 3 (1, 6) |
| Year of diagnosis | |||||
| 2004 | 393 (5%) | 258 (5%) | 75 (5%) | 27 (8%) | 33 (3%) |
| 2005 | 456 (6%) | 301 (6%) | 79 (5%) | 29 (8%) | 47 (5%) |
| 2006 | 478 (6%) | 309 (6%) | 110 (7%) | 18 (5%) | 41 (4%) |
| 2007 | 609 (8%) | 361 (7%) | 150 (10%) | 26 (7%) | 72 (7%) |
| 2008 | 607 (8%) | 383 (8%) | 124 (8%) | 27 (8%) | 73 (7%) |
| 2009 | 680 (9%) | 453 (9%) | 114 (7%) | 27 (8%) | 86 (9%) |
| 2010 | 765 (10%) | 463 (9%) | 160 (10%) | 40 (11%) | 102 (10%) |
| 2011 | 827 (11%) | 514 (11%) | 169 (11%) | 36 (10%) | 108 (11%) |
| 2012 | 887 (11%) | 563 (12%) | 161 (10%) | 41 (12%) | 122 (13%) |
| 2013 | 996 (13%) | 633 (13%) | 195 (12%) | 44 (12%) | 124 (13%) |
| 2014 | 1,093 (14%) | 651 (13%) | 234 (15%) | 40 (11%) | 168 (17%) |
| PSA (ng/mL) | 9 (6, 18) | 9 (5, 16) | 11 (7, 21) | 10 (6, 20) | 10 (6, 20) |
| Grade group | |||||
| 1-2 | 1,618 (21%) | 1,176 (24%) | 203 (13%) | 77 (22%) | 162 (17%) |
| 3 | 2,095 (27%) | 1,360 (28%) | 384 (24%) | 105 (30%) | 246 (25%) |
| 4 | 1,187 (15%) | 742 (15%) | 256 (16%) | 42 (12%) | 147 (15%) |
| 5 | 2,749 (35%) | 1,527 (31%) | 700 (45%) | 116 (33%) | 406 (42%) |
| Unknown | 142 (2%) | 84 (2%) | 28 (2%) | 15 (4%) | 15 (2%) |
| Pathologic stage | |||||
| T2 | 1,401 (18%) | 1,077 (22%) | 181 (12%) | 47 (13%) | 96 (10%) |
| T3a | 2,294 (29%) | 1,511 (31%) | 437 (28%) | 110 (31%) | 236 (24%) |
| T3b | 3,747 (48%) | 2,116 (43%) | 861 (55%) | 181 (51%) | 589 (60%) |
| T4 | 280 (4%) | 138 (3%) | 78 (5%) | 12 (3%) | 52 (5%) |
| Unknown | 69 (<1%) | 47 (<1%) | 14 (<1%) | 5 (1%) | 3 (<1%) |
| Surgical margins | |||||
| Negative | 4,068 (52%) | 2,898 (59%) | 680 (43%) | 147 (41%) | 343 (35%) |
| Positive | 3,652 (47%) | 1,956 (40%) | 873 (56%) | 204 (57%) | 619 (63%) |
| Unknown | 71 (<1%) | 35 (<1%) | 18 (1%) | 4 (1%) | 14 (1%) |
| Positive LN count | 1 (1, 2) | 1 (1, 2) | 1 (1, 3) | 1 (1, 2) | 1 (1, 2) |
| LN yield | 9 (5, 14) | 9 (5, 14) | 9 (5, 14) | 7 (4, 12) | 8 (4, 13) |
Categorical and continuous variables reported as counts (percentages) and medians (interquartile range), respectively; CCI, race and insurance categories collapsed to comply with NCDB stipulation against reporting counts <10; percentages may not add up to 100% because of rounding; ADT, androgen deprivation therapy; LN, lymph node; PSA, prostate-specific antigen; RT, radiation therapy